-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hematopoietic stem cell transplantation (HSCT) is currently an effective treatment for hematological malignancies (leukemia, myeloma, and lymphoma ) and other hematological diseases (myelodysplasia and aplastic anemia)
.
However, in view of the widespread nature of human leukocyte antigen (HLA) polymorphisms and the small-scale nature of modern families, most patients requiring hematopoietic stem cell transplantation do not have an HLA-matched donor
Stem cell lymphoma
HLA-haploid transplantation has rapidly spread worldwide, and cord blood (CB) is also a good alternative source of hematopoietic stem cells
.
Umbilical cord blood has many advantages as a source of stem cells
immunity
More and more evidence shows that for patients who lack relatives and HLA-matched non-relative donors, haploid donors and CB are promising options
.
Although the recovery of hematopoietic function is delayed, the incidence of acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD) is lower in UCBT recipients
Unfortunately, UCBT is usually accompanied by the emergence of unique early immune responses that have appeared before neutrophil transplantation
.
Lee et al.
Severe PES cases are associated with increased mortality and morbidity.
GM-CSF produced by inflammatory monocytes in cord blood drives the pathological changes of PES.
Clinical symptoms and manifestations before and after treatment with tocilizumab
Clinical symptoms and manifestations before and after treatment with tocilizumab Clinical symptoms and manifestations before and after treatment with tocilizumabIn addition, the researchers also reported the results of a single-arm, single-center clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients ( ChiCTR1800015472)
.
The study reached the main outcome indicator because none of the patients had a non-recurring death during the 100-day follow-up
Single-arm, single-center clinical research results Single-arm, single-center clinical research results reached the main outcome indicators reached the main outcome indicators reached the key secondary outcome indicators for neutrophil transplantation and hematopoiesis reached the neutrophil transplantation and hematopoiesis Key secondary outcome indicators
These findings provide a treatment strategy for solving PES and improving non-relapse mortality
Original source:
Original source:Linlin Jin et al.
Linlin Jin et al.
Leave a message here